Investors were tripping over themselves to buy Dr Martens (DOCS) after the iconic British footwear brand announced a return to profit growth.
FY26 results confirmed the footwear retailer’s Levers for Growth strategy is gaining traction.
Reduced discounting and a pivot to a ‘truly consumer-first’ business model are paying off for the FTSE 250 firm.
Positive strides
Dr Martens’ adjusted pre-tax profits powered 61% higher to £55 million for the year to March 2026. Profit growth was delivered despite a 29% drop in revenue to £764.9 million as the boot brand pulled back on clearance activity.
The retailer said the move was designed to improve the quality of its revenues and protect margins as part of CEO Ije Nwokorie’s turnaround strategy.
The company behind the iconic 1460 boot and Adrian loafer reported a 120 basis point uptick in gross margin to 66.2%. This reflected continued tight cost control and improved full price mix. The Americas proved the best performing region, with full price direct-to-consumer revenues up 14%.
Standout showing from shoes
Nwokorie commented: ‘Shoes were the standout performer, up 19%. Our focus on execution is paying off: we are improving the quality of revenues whilst strengthening margins, cash generation, the balance sheet and overall model resilience.’
The CEO insisted: ‘Desire for the Dr Martens brand continues to grow, with more collaborators approaching us, increased wholesale partner support, strong consumer response to new product families, and an excited reaction from the market to our first beacon store on Brewer Street, London.’
Dr Martens’ increasingly looks like a compelling recovery story. The company has returned to profit growth, is weaning itself off margin-eroding discounts and paying down debt.
Encouragingly, the footwear brand expects to generate ‘further strong pre-tax profit growth’ in FY27. This will be driven by operational leverage and a stronger wholesale order book.
At these levels, there looks like plenty of upside for the shares. Dr Martens has shed over 80% of its value since the firm’s 2021 initial public offering (IPO) at 370p. If the turnaround success continues, Dr Martens could even attract a takeover bid before too long.
Read the press release here: https://www.drmartensplc.com/investors/
You might also like these stories:
